Document is current

Article History

Received: 30 August 2024

Accepted: 30 May 2025

First Online: 20 June 2025

Declarations

:

: MM, ET, IR, and ML are employees of Chiesi Farmaceutici S.p.A. YP and IM were employees of Chiesi Farmaceutici S.p.A. at the time of the study. PK received honoraria for review of the interview guide and questionnaires, and is a consultant for Chiesi Farmaceutici SpA. The associations represented by MP and SB (FederAsma e Allergie ODV-Federazione Italiana Pazienti and Associazione Nazionale Pazienti Respiriamo Insieme) received donations/sponsorships from Chiesi Farmaceutici S.p.A. AT was an employee of Doxa Pharma at the time of the study and was commissioned by Chiesi Farmaceutici S.p.A. to conduct research. IC and LF are employees of Rebus Medical Limited and were commissioned by Chiesi Farmaceutici S.p.A. to conduct research.

: This study was conducted online, and no healthcare practitioners were involved in patient recruitment. The survey fell under the scope of market research and did not fall under the scope of regulations regarding clinical/observational studies or research involving humans. Therefore, submission to an ethical committee was not required. This research was conducted in accordance with the 1964 Declaration of Helsinki, and its later amendments, as well as British Healthcare Business Intelligence Association’s Legal & Ethical Guidelines for Market Research, the European Pharmaceutical Market Research Association, the European Society for Opinion and Market Research, and the Assirm Codes of Conduct. Informed consent regarding participation and publication of outcomes were obtained from all individual participants included in the study.

: Not applicable.

: Obtained prior to initiating interview or survey.